Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Cholangiocarcinoma 2Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myelodysplastic Syndromes 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 14Radiotherapy 12Trastuzumab 10Lomustine 9Capecitabine 8paclitaxel-Angiopep-2 conjugate 6Nivolumab 6pembrolizumab 5dabrafenib 5abemaciclib 5Radiation 5icotinib 4Surgical Procedures, Operative 4Paclitaxel 4Lapatinib 4Irinotecan 4Flucytosine 4Dianhydrogalactitol 4Corticotropin-Releasing Hormone 4Chlorotoxin 4Carboplatin 4vocimagene amiretrorepvec 3verubulin 3tucatinib 3osimertinib 3motexafin gadolinium 3XL647 3Spermine Synthase 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Brain Neoplasms × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡